Erbitux (cetuximab) / BMS, Eli Lilly, EMD Serono - LARVOL DELTA

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients (ASH 2025) - "The most common CAR T-cell products wereaxicabtagene ciloleucel (n = 31, 25%), brexucabtagene autoleucel (n = 26, 21%), and tisagenlecleucel (n =21, 17%)...Nearly all (n = 123; 99%) patients received concurrent dexamethasone (dex) with a median totaldose of 234 mg (range, 30-690)...Sixteen patients (13%)received additional therapies, including ruxolitinib (n = 1), siltuximab (n = 3), cetuximab (n = 1), intrathecalchemotherapy (n = 11), and dasatinib (n = 1)...Higher dex doses remainedassociated with shorter time to ICANS resolution, highlighting that corticosteroids remain thecornerstone of treating refractory ICANS. More effective strategies for anakinra-refractory ICANS arecritically needed."

CAR T-Cell Therapy • B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

BI08 A prospective observational study exploring the incidence and impact of cutaneous toxicities in patients undergoing oncological treatment. (PubMed, Br J Dermatol) - "The most frequently observed immunotherapy agent causing cutaneous toxicity was pembrolizumab (20%). Cetuximab and bevacizumab were the most common culprit targeted therapies (both 7%)...Cutaneous toxicities may impact on QoL. Decisions regarding alterations to treatment plans due to cutaneous toxicities should be made in collaboration by oncologists and dermatologist."

Journal • Observational data • CNS Disorders • Dermatology • Eosinophilia • Lung Cancer • Melanoma • Oncology • Psychiatry • Solid Tumor • Steven-Johnson Syndrome

Prevalence of HRAS mutations in metastatic head and neck squamous cell carcinoma: A preliminary study from India (ESMO Asia 2025) - "Tipifarnib, a FTase inhibitor, has been given FDA approval for high VAF HRAS positive HNSCC. HRAS mutations have been shown to have poor response to cetuximab in first-line recurrent metastatic setting... This preliminary study demonstrates a notably high prevalence (20%) of HRAS mutations among Indian patients with metastatic HNSCC highlighting the potential for integrating HRAS-targeted therapies into future clinical management protocols in India."

Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • HRAS

Conversion rates to surgery or radiotherapy with neoadjuvant cetuximab-based therapy in locally advanced head and neck squamous cell carcinoma: AI-assisted peripheral immune biomarkers analysis (ESMO Asia 2025) - "In this real-world cohort, neoadjuvant cetuximab-based therapy was directly responsible for a high conversion rate to surgery or RT, perfectly aligning with tumour response. AI/ML-assisted analysis identified baseline NLR and ALC as predictors of response and conversion in HNSCC. This approach can accelerate biomarker discovery and aid personalised treatment planning."

Biomarker • Clinical • Metastases • Surgery • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Radiation-induced upregulation of PD-LI is blunted by acquired resistance to cetuximab and/or ruxolitinib (ESMO Asia 2025) - "Radiation treatment resulted in upregulation of PD-LI for HNSCC cells. Also, EGFR-JAK/STAT signaling is known to play a role in activation of PD-LI. Acquired resistance to the anti-EGFR agent cetuximab and/or the anti-JAK/STAT agent ruxolitinib was found to significantly blunt radiation-induced activation of PD-LI."

Preclinical • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

Establishing a microfluidic liquid-biopsy platform for prognosticating head and neck cancer with the DS-SACA chip (ESMO Asia 2025) - "With just 2 mL of blood, SACA simultaneously enumerates tumor and immune components in advanced HNSCC. Rising CTC curves reflect tumor burden; CTM-linked CD14+ cells signal resistance and poor prognosis; and cetuximab lowers CD11b+ suppressor cells. SACA therefore offers a rapid, integrated liquid-biopsy readout that has potential to guide personalized therapy."

Biopsy • Liquid biopsy • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CD14 • CTCs • ITGAM • NCAM1 • PTPRC

Induction serplulimab and cetuximab combined with chemotherapy followed by radiotherapy for unresectable locally advanced HNSCC: A single-arm, prospective, phase II study (ESMO Asia 2025) - "Patients received serplulimab (4.5 mg/kg, Q3W) + cetuximab (400 mg/m2 loading, followed by 250 mg/m2, QW) + liposomal paclitaxel (135 mg/m2, D1) + cisplatin (75 mg/m2, Q3W), for 3 weeks per cycle, with 2 total treatment cycles. In patients with unresectable LA-HNSCC, this induction regimen showed preliminary efficacy and manageable toxicity. Further follow-up is required to confirm the survival benefit."

Clinical • Metastases • P2 data • Head and Neck Cancer • Hypopharyngeal Cancer • Nasopharyngeal Carcinoma • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Cetuximab in maintenance after induction, right-sided tumors, and rechallenge in metastatic colorectal cancer: Insights from real-world practice in India (ESMO Asia 2025) - "Findings support the extended role of cetuximab in line with current ESMO guidelines. This is the first study to report real-world outcomes from Indian population, and demonstrates the potential for flexible anti-EGFR use tailored to patient selection and prior treatment history in mCRC, offering valuable regional insights to global evidence."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Cetuximab combined with chemotherapy in RAS wild-type metastatic colorectal cancer: A real-world study in Indian settings (ESMO Asia 2025) - "In the induction phase, most patients received FOLFOX (67), followed by FOLFIRI (18), with smaller numbers on CAPOX (3), IRIS (1), and 12 missing... This real-world evidence analysis reinforces the established benefit of cetuximab combined with chemotherapy in RAS WT, left-sided mCRC patients. These findings are aligned with the outcomes from major trials such as CALGB 80405 (PFS: 10.45 months) and ASCO 2016 analyses (PFS: 11.4 months). Notably, this is the first such study from the Indian subcontinent, reflecting outcomes in a heterogeneous patient population and adding valuable regional RWD to the global evidence base."

Clinical • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Real-world observational study of fruquintinib in combination with irinotecan and capecitabine as second-line treatment in patients with advanced colorectal cancer (ESMO Asia 2025) - P | "11 (52.4%) and 4 (19.0%) patients had received bevacizumab and cetuximab as part of their first-line treatment. These results show the preliminary efficacy and safety of fruquintinib in combination with irinotecan and capecitabine as a second-line treatment for patients with advanced colorectal cancer."

Clinical • Combination therapy • Metastases • Observational data • Real-world • Real-world evidence • Colorectal Adenocarcinoma • Colorectal Cancer • Oncology • Solid Tumor • UGT1A1

First-line panitumumab versus cetuximab for all RAS wild-type metastatic colorectal cancer: Survival and metastatic-site resection in a Taiwanese Multicenter cohort (ESMO Asia 2025) - "First-line panitumumab and cetuximab achieved similar OS, but panitumumab was consistently associated with higher metastatic-site resection rates. Metastasectomy was linked to markedly prolonged survival, supporting panitumumab's potential in conversion therapy."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • EGFR • RAS

First-line (1L) encorafenib + cetuximab + mFOLFOX6 in East Asian patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC): Results from the phase III BREAKWATER study (ESMO Asia 2025) - P3 | "Background: The randomized phase 3 BREAKWATER study (NCT04607421) demonstrated statistically significant and clinically meaningful improvements in ORR by blinded independent central review (BICR), PFS by BICR, and OS with encorafenib + cetuximab (EC) + mFOLFOX6 vs control (chemotherapy ± bevacizumab) in 1L BRAF V600E-mutant mCRC (Kopetz, Nat Med 2025; Elez, N Engl J Med 2025)... Consistent with the global study results, East Asian pts with untreated BRAF V600E-mutant mCRC attained clinically significantly improved ORR, PFS, and OS with EC+mFOLFOX6 vs control therapy. The treatment safety profiles in East Asian pts were consistent with those observed in the overall population and as expected for each agent."

Clinical • Metastases • P3 data • Colorectal Cancer • Oncology • Solid Tumor • BRAF

MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001 (ESMO Asia 2025) - P1 | "In arm 6, pts with advanced CRC and 0-1 prior systemic therapies received MK-1084 (total daily dose 25-100 mg) plus cetuximab 500 mg/m2 Q2W and mFOLFOX6... Updated data continue to show manageable safety profiles and evidence of antitumor activity for MK-1084–based regimens in pts with advanced, KRAS G12C-mutated CRC. The phase 3 KANDLELIT-012 study is evaluating MK-1084 + cetuximab + mFOLFOX as first-line therapy for KRAS G12C-mut advanced CRC."

Metastases • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Colorectal Cancer • Oncology • Solid Tumor

INTERLINK-1: Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - P3 | N=370 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Sep 2025 ➔ Sep 2026

Checkpoint inhibition • Trial completion date • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Indian Hedgehog expression and association with cetuximab benefit in metastatic colorectal cancer (mCRC): Evidence from CALGB (Alliance)/SWOG 80405. (ASCO-GI 2026) - "Funded by National Cancer Institute, Genentech The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for PIK3CA-mutated (mut) metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P1 | "Funded by F. Hoffmann-La Roche Ltd Clinical Trial Registration Number: NCT04929223 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PIK3CA

Circulating tumor DNA to guide rechallenge with cetuximab plus irinotecan in Chinese RAS/BRAF wild type metastatic colorectal cancer: A phase II trial. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT04224415 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Circulating tumor DNA • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • RAS

Second-line irinotecan followed by third-line cetuximab plus irinotecan versus second-line cetuximab combined with irinotecan in treatment of oxaliplatin/5-FU failure RAS/RAF wild-type mCRC patients: A randomized phase II study. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT04833036 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • P2 data • Colorectal Cancer • Gastrointestinal Cancer • RAS

Efficacy and safety of triweekly cetuximab in combination with capecitabine as first-line maintenance treatment for KRAS/BRAF wild-type metastatic colorectal cancer: A phase Ib dose-escalation study. (ASCO-GI 2026) - P1/2 | "Funded by Beijing Bethune Charitable Foundation Clinical Trial Registration Number: NCT05775900 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Metastases • P1 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • KRAS

T-CORE2401 trial: A randomized phase II trial of mFOLFOX6 plus cetuximab versus mFOLFOX6 plus bevacizumab as first-line treatment for right-sided, RAS/BRAF wild-type, low-methylated metastatic colon cancer. (ASCO-GI 2026) - "Funded by Tohoku University Hospital, Japan Society of Clinical Oncology (JSCO) Clinical Trial Registration Number: 1021240067 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF • RAS

Phase 1 dose escalation and expansion study of TROP2 CAR-engineered IL-15-transduced cord blood-derived NK cells in combination with cetuximab in patients with colorectal cancer (CRC) with minimal residual disease (MRD). (ASCO-GI 2026) - P1 | "Funded by ASCO CDA Clinical Trial Registration Number: NCT06358430 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Combination therapy • Minimal residual disease • P1 data • Residual disease • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • IL15

KANDLELIT-012: Phase 3 study of MK-1084 (a KRAS G12C inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for KRAS G12C-mutant colorectal cancer. (ASCO-GI 2026) - P3 | "Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Clinical Trial Registration Number: NCT06997497 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

P3 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • KRAS

Phase 2 study of combined therapy FOLFOX with dabrafenib and cetuximab/panitumumab as first-line treatment for patients with metastatic colorectal cancer MSS with BRAF V600E mutation. (ASCO-GI 2026) - P2 | "Clinical Trial Registration Number: NCT06978400 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • P2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF

BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P3 | "Funded by Pfizer Clinical Trial Registration Number: NCT04607421 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Clinical • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF